Stroke Trials Network of Columbia and Cornell

哥伦比亚大学和康奈尔大学中风试验网络

• 批准号: 10306036
• 负责人: EDWARD SANDER CONNOLLY
• 金额: $ 31.68万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-08-15 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10306036
• 关键词: Academic Medical Centers; Acute; Admission activity; Adult; African American; Ancillary Study; Area; Asians; Biological Markers; Carotid Stenosis; Childhood stroke; Clinical; Clinical Research; Clinical Trials; Cognition; County; Data; Development; Disease; Enrollment; Failure; Fellowship; Funding; Goals; Heart Atrium; Hispanics; Hospitals; Human; Infrastructure; Institution; K-Series Research Career Programs; Leadership; Manuscripts; Mentors; Minority Groups; Neurologist; Neurosciences; New Jersey; New York; Outcome Study; Patients; Phase; Phase II Clinical Trials; Phase III Clinical Trials; Population; Populations at Risk; Positioning Attribute; Productivity; Randomized Controlled Trials; Recovery; Rehabilitation Centers; Rehabilitation therapy; Resources; Role; Science; Side; Site; Standardization; Stroke; Stroke prevention; Testing; Training; Training and Education; United States National Institutes of Health; Work; acute stroke; career; cerebral hemodynamics; clinical trial enrollment; cryptogenic stroke; demographics; disability; experience; improved; innovation; medical schools; mortality; multi-ethnic; neurosurgery; next generation; patient subsets; professor; programs; screening; stroke clinical trials; stroke outcome; stroke recovery; stroke therapy; stroke trials; success; treatment center; underserved minority; working group

The Stroke Trials Network of Columbia and Cornell (STNCC) has a primary goal of maximizing stroke clinical trial enrollment for New York. Columbia and Cornell, situated on the west and east side of Manhattan, respectively, will form the two hubs, supported by an Acute Treatment Sub-network of 3 hospitals in Brooklyn and New Jersey, a Recovery Sub-network comprising 2 affiliated academic Rehabilitation Centers in Westchester County and New Jersey, and 4 Academic Medical Centers in Brooklyn and in Western New York. Our hubs and satellites treated just over 6,700 strokes in 2016. More importantly, our RCC has an extensive leadership record in stroke clinical trials, and have the distinction of being the leading enroller in Stroke clinical trials over the first 5 years of StrokeNet; Our total enrollment as of August, 2017 was 375 subjects. Historically, over the last 10 years, Columbia and Cornell have been involved in 44 human stroke studies, including 29 stroke clinical trials, 10 stroke biomarker studies, and 5 stroke outcomes studies. The demographics in our network overall are very favorable for enrolling underserved minority populations: Columbia has 40% Hispanic and 25% African American; Cornell 15% Asian, and St. Joseph's 24% African American, 30% Hispanic, 12% other. Part of our success is due to the highly organized and interactive infrastructure. We hold monthly videoconferences attended by PIs and coordinators from all RCC hubs and satellite sites, and standardized daily stroke admission screening across the RCC. These data as well as trial enrollments are reviewed at the monthly videoconference calls. The STNCC has also provided leadership at the national level in the first 5 years of StrokeNet. Contact PI Randolph Marshall served on the NCC Executive Committee for the first 3 years, as Co-Chair of the Education and Training Core for all 5 years, and on the Recovery and Rehabilitation Working Group over the last year. He has been invited to continue the latter two roles in the upcoming renewal period. Co-I Ronald Lazar, now at UAB, served on the Recovery and Rehab WG for three years, and Co-PI E Sander Connolly has served on the Neurosurgery advisory group. In terms of innovation and clinical trial development, our RCC has the distinction of submitting and obtaining funding for two of the new StrokeNet studies. STNCC Co-Is Mitchell Elkind and Hooman Kamel are Co-PI's on the ARCADIA trial, a multi-center Phase 3 RCT to determine whether apixaban is superior to standard therapy for patients with cryptogenic stroke and “atrial cardiopathy.” Randolph Marshall, Sander Connolly, and Ronald Lazar are Co-PI's on the CREST-H study, an ancillary study to the CREST-2 trial, testing the hypothesis that revascularization can improve cognition in as subset of patients with high grade asymptomatic carotid stenosis who have cerebral hemodynamic failure. Finally, our StrokeNet trainee program has been highly successful, with 5 trainees producing 22 abstracts and 21 manuscripts within 1 year of Fellowship, and 4 so far have Assistant Professor positions at major academic institutions (all StrokeNet sites). Two are applying for K-awards.

哥伦比亚和康奈尔（STNCC）的中风试验网络的主要目标是 最大化纽约的中风临床试验入学率。哥伦比亚和康奈尔，位于 曼哈顿的西侧和东侧分别将形成两个枢纽，并由急性支撑 布鲁克林和新泽西州的3家医院的治疗子网络，这是一个恢复子网 在威彻斯特县和新泽西州完成2个会员学术康复中心 布鲁克林和纽约西部的4个学术医疗中心。我们的轮毂和卫星 在2016年接受了6,700多杆的治疗。更重要的是，我们的RCC具有广泛的领导 中风临床试验中的记录，并具有中风领先的入学者的区别 在Strokenet的前5年进行临床试验；截至2017年8月，我们的总入学人数为375 主题。从历史上看，在过去的十年中，哥伦比亚和康奈尔大学参与了44 人类中风研究，包括29项中风临床试验，10个中风生物标志物研究和5个 中风结果研究。我们网络中的人口统计总体非常有利 招募服务不足的少数民族人口：哥伦比亚有40％的西班牙裔和25％的非洲人 美国人;康奈尔（Cornell）15％的亚洲人和圣约瑟夫（St. Joseph）的24％非裔美国人，30％西班牙裔，12％ 其他。我们成功的一部分是由于高度有条理和互动的基础设施。我们抱着 PIS和所有RCC枢纽和卫星的协调员参加的每月视频会议 站点和标准化的每日中风门票筛查遍布RCC。这些数据也 在每月的视频会议呼叫中审查试用注册人数。 STNCC也有 在Strotenet的头五年中，在国家一级提供领导。联系Pi Randolph 马歇尔（Marshall）担任NCC执行委员会的头三年，担任 教育和培训核心已有5年，以及恢复和康复工作 在过去的一年中。曾邀请他继续在即将到来的后两个角色 续期。现在在UAB的Co-i Ronald Lazar在恢复和康复WG任职 三年来，桑德·康诺利（Co-Pi e Sander Connolly）曾在神经外科咨询小组任职。在 创新和临床试验开发条款，我们的RCC具有提交的区别 并为两项新的跨语研究获得资金。 STNCC Co-is Mitchell Elkind和 Hooman Kamel是Co-Pi的Arcadia试验，这是一个多中心3阶段RCT apixaban是否优于隐性中风患者的标准疗法 心脏病。 Crest-H研究是Crest-2试验的辅助研究，检验了以下假设 血运重建可以改善高级无症状患者的AS的认知 颈动脉狭窄，患有脑血液动力学衰竭。最后，我们的Strokenet实习生计划 已经非常成功，有5个学员生产22个摘要和21个手稿。 奖学金的年份，到目前为止有4年有主要学术的助理教授职位 机构（所有拼写网站）。两个正在申请K瓦。